ERBB3 and cancer: Additional preclinical and clinical data as well as data integration will help identify a predictive biomarker for HER3-targeted therapy, and greater clinical benefits might be attained by combining HER3-targeted therapy with other cancer-targeting antibodies and/or small-molecule TKIs.